• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
CONCLUSIONS: The HIF-1α protein in MMECs may induce angiogenesis and resistance to bortezomib and lenalidomide and be a plausible target for the antiangiogenic management of well defined relapsed/refractory MM patients. It may also have prognostic significance. PMID: 24297864 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 2, 2013 Category: Cancer & Oncology Authors: Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, Ruggieri V, Frassanito MA, Ribatti D, Nico B, Annese T, Ruggieri S, Guarini A, Minoia C, Ditonno P, Angelucci E, Derudas D, Moschetta M, Dammacco F, Vacca A Tags: Clin Cancer Res Source Type: research

Long noncoding RNA H19 promotes vincristine resistance in multiple myeloma by targeting Akt.
Authors: Wang Y, Xu S, Wang L, Liu J, Wang J, Zhou J Abstract Multiple myeloma is a malignant proliferation of plasma cells that results from a single clone. Manifestations include bone pain or fractures, kidney failure, susceptibility to infection, anemia, and hypercalcemia. To investigate the relationship between vincristine (VCR) resistance and Long noncoding RNA H19 (Lnc-RNA H19) in multiple myeloma (MM) this experiment was set up. For this aim, RT-PCR was used to detect the expression of lnc-RNA H19 in 60 MM patients from No.215 Hospital of Shaanxi Nuclear Industry and 50 healthy controls, and further detected...
Source: Cellular and Molecular Biology - October 14, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
CONCLUSIONS: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel MM therapy. PMID: 28270494 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC Tags: Clin Cancer Res Source Type: research